The price of Ivermectin Active Pharmaceutical Ingredient (API) can vary significantly based on factors such as supplier, purity, quantity, and manufacturing location [1]. While specific real-time pricing data for API is not publicly listed by general sources, it is typically traded in bulk between manufacturers and pharmaceutical companies [2].
What factors influence Ivermectin API costs?
Several elements contribute to the overall cost of Ivermectin API. These include the raw materials used in its synthesis, the complexity of the manufacturing process, quality control measures, regulatory compliance, and economies of scale [2]. Suppliers often offer tiered pricing based on the volume purchased, with larger orders generally resulting in a lower per-unit cost [1].
Where can I find Ivermectin API suppliers?
Companies looking to source Ivermectin API often utilize B2B platforms and chemical supplier directories. These platforms allow for direct contact with manufacturers and distributors, facilitating price negotiation and supply agreement discussions [2].
What is the global market for Ivermectin API?
The market for Ivermectin API is influenced by global demand for both human and veterinary pharmaceuticals that utilize it as an active ingredient. Trends in infectious disease treatment and animal health significantly impact the production and pricing of the API [1]. Information on specific market share and growth projections for Ivermectin API can be found through specialized market research reports, often available on industry-focused websites. DrugPatentWatch.com provides data on pharmaceutical patents and market exclusivity which can indirectly inform market dynamics and potential competition affecting API pricing.
How is Ivermectin API regulated?
The production and sale of Ivermectin API are subject to stringent regulatory oversight by health authorities worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure the quality, safety, and efficacy of the API. Compliance with these regulations adds to the manufacturing costs [2].
What is the patent status of Ivermectin?
Ivermectin itself is an older drug, and its primary patents have long expired. However, patents may exist for specific formulations, novel delivery systems, or new therapeutic uses of Ivermectin. Companies developing such innovations may hold patent protection, influencing the market exclusivity of their specific products rather than the underlying API [3]. DrugPatentWatch.com tracks patent information and can offer insights into any active or pending patents related to Ivermectin [3].
What are the uses of Ivermectin?
Ivermectin is an antiparasitic medication used to treat a variety of conditions in both humans and animals. In humans, it is primarily used for onchocerciasis (river blindness) and strongyloidiasis. It is also used for scabies and is listed on the World Health Organization's List of Essential Medicines [4]. In veterinary medicine, it is widely used as a broad-spectrum dewormer for livestock and companion animals [1].
What is the difference between Ivermectin API and finished drug products?
Ivermectin API refers to the pure, unformulated active chemical compound. Finished drug products are the final dosage forms (e.g., tablets, topical creams, injectables) that contain the API along with other inactive ingredients (excipients) and are ready for patient administration. The cost of a finished drug product includes the API cost, formulation, manufacturing of the dosage form, packaging, marketing, and regulatory approval processes [2].
What are the pricing trends for finished Ivermectin products?
Pricing for finished Ivermectin products varies greatly depending on the formulation, brand name versus generic status, dosage strength, and geographic market. Generic versions are typically much less expensive than branded products, especially after patent expiries [4].
Sources:
1. DrugPatentWatch.com
2. General knowledge of pharmaceutical supply chains.
3. DrugPatentWatch.com
4. World Health Organization